Samir Aoudjane1, Mas Chaponda2, Antonio Adrián González Del Castillo1, Jemma O'Connor3, Marc Noguera4, Apostolos Beloukas5, Mark Hopkins6, Saye Khoo7, Joep J van Oosterhout8, Anna Maria Geretti5. 1. Division of Infection & Immunity and London Centre for Nanotechnology. 2. Department of Infectious Diseases, University of Liverpool/Malawi Liverpool Wellcome Trust, United Kingdom. 3. Department of Infection & Population Health, University College London. 4. IrsiCaixa & AIDS Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. 5. Institute of Infection and Global Health. 6. Department of Virology. 7. Institute of Translational Medicine, University of Liverpool, United Kingdom. 8. College of Medicine, University of Malawi, Blantyre Dignitas International, Zomba, Malawi.
Abstract
BACKGROUND: It has been proposed that hepatitis B virus (HBV) sub-genotype A1 infections have mild outcomes and a low risk of drug-resistance among patients infected with human immunodeficiency virus (HIV) receiving lamivudine-containing antiretroviral therapy (ART) without tenofovir in Africa. METHODS: The virologic expression of HBV sub-genotype A1 coinfection was studied over 12 months in HIV-positive adults starting stavudine/lamivudine/nevirapine in Malawi, using Sanger, deep, clonal, and single full-genome sequencing for the sensitive characterization of HBV resistance-associated mutations (RAMs). RESULTS: Among 1117 subjects, 133 (12%) tested HBsAg-positive. After starting ART, retention rates were 96/133 (72%) at 6 months and 54/133 (41%) at 12 months. Based upon the last available follow-up, 92/96 (96%) subjects achieved HIV-1 RNA <40 copies/mL, 48/96 (50%) showed HBV DNA <14 IU/mL, and 24/96 (25%) acquired HBV RAMs. At 6 months, M204I was detected in 8/46 (17%) and 16/17 (94%) subjects using Sanger and deep sequencing, respectively. At 12 months, all viremic patients had multiple resistance and compensatory mutations coexisting on the same HBV genomes. Comparing HBeA-positive (67/133, 50%) with HBeAg-negative subjects, 64/67 (96%) vs 35/66 (55%) showed baseline HBV DNA >2000 IU/mL (P = .0006), 39/47 (17%) vs 9/49 (82%) had persistent HBV DNA detection during follow-up (P < .0001), and 23/47 (49%) vs 2/49 (4%) acquired HBV RAMs (P < .0001). Baseline HBV DNA levels were median 8.1 vs 5.3 log10 IU/mL in subjects with vs those without treatment-emergent RAMs (P < .0001). CONCLUSIONS: HBV sub-genotype A1 infections showed a severe virologic expression in HIV-positive Malawians. The findings strengthen the urgency of interventions to improve ascertainment and management of chronic hepatitis B in the region.
BACKGROUND: It has been proposed that hepatitis B virus (HBV) sub-genotype A1 infections have mild outcomes and a low risk of drug-resistance among patients infected with human immunodeficiency virus (HIV) receiving lamivudine-containing antiretroviral therapy (ART) without tenofovir in Africa. METHODS: The virologic expression of HBV sub-genotype A1 coinfection was studied over 12 months in HIV-positive adults starting stavudine/lamivudine/nevirapine in Malawi, using Sanger, deep, clonal, and single full-genome sequencing for the sensitive characterization of HBV resistance-associated mutations (RAMs). RESULTS: Among 1117 subjects, 133 (12%) tested HBsAg-positive. After starting ART, retention rates were 96/133 (72%) at 6 months and 54/133 (41%) at 12 months. Based upon the last available follow-up, 92/96 (96%) subjects achieved HIV-1 RNA <40 copies/mL, 48/96 (50%) showed HBV DNA <14 IU/mL, and 24/96 (25%) acquired HBV RAMs. At 6 months, M204I was detected in 8/46 (17%) and 16/17 (94%) subjects using Sanger and deep sequencing, respectively. At 12 months, all viremic patients had multiple resistance and compensatory mutations coexisting on the same HBV genomes. Comparing HBeA-positive (67/133, 50%) with HBeAg-negative subjects, 64/67 (96%) vs 35/66 (55%) showed baseline HBV DNA >2000 IU/mL (P = .0006), 39/47 (17%) vs 9/49 (82%) had persistent HBV DNA detection during follow-up (P < .0001), and 23/47 (49%) vs 2/49 (4%) acquired HBV RAMs (P < .0001). Baseline HBV DNA levels were median 8.1 vs 5.3 log10 IU/mL in subjects with vs those without treatment-emergent RAMs (P < .0001). CONCLUSIONS:HBV sub-genotype A1 infections showed a severe virologic expression in HIV-positive Malawians. The findings strengthen the urgency of interventions to improve ascertainment and management of chronic hepatitis B in the region.
Authors: E Moore; M B J Beadsworth; M Chaponda; B Mhango; B Faragher; J Njala; H W C Hofland; J Davies; I J Hart; N J Beeching; E E Zijlstra; J J van Oosterhout Journal: J Infect Date: 2010-05-12 Impact factor: 6.072
Authors: Gail V Matthews; Prince Manzini; Zonghui Hu; Paul Khabo; Patrick Maja; Gugu Matchaba; Phumele Sangweni; Julie Metcalf; Nicholaas Pool; Susan Orsega; Sean Emery Journal: AIDS Date: 2011-09-10 Impact factor: 4.177
Authors: Lara Stabinski; Steven J Reynolds; Ponsiano Ocama; Oliver Laeyendecker; Anthony Ndyanabo; Valerian Kiggundu; Iga Boaz; Ron H Gray; Maria Wawer; Chloe Thio; David L Thomas; Thomas C Quinn; Gregory D Kirk Journal: Antivir Ther Date: 2011
Authors: John Archer; Greg Baillie; Simon J Watson; Paul Kellam; Andrew Rambaut; David L Robertson Journal: BMC Bioinformatics Date: 2012-03-23 Impact factor: 3.169
Authors: Natasha K Martin; Angela Devine; Jeffrey W Eaton; Alec Miners; Timothy B Hallett; Graham R Foster; Gregory J Dore; Philippa J Easterbrook; Rosa Legood; Peter Vickerman Journal: AIDS Date: 2014-01 Impact factor: 4.177
Authors: Simon J Watson; Matthijs R A Welkers; Daniel P Depledge; Eve Coulter; Judith M Breuer; Menno D de Jong; Paul Kellam Journal: Philos Trans R Soc Lond B Biol Sci Date: 2013-02-04 Impact factor: 6.237
Authors: Alexander J Stockdale; Niza M Silungwe; Isaac Thom Shawa; Benno Kreuels; Melita A Gordon; Anna Maria Geretti Journal: BMC Infect Dis Date: 2021-05-27 Impact factor: 3.090
Authors: Philippa C Matthews; Apostolos Beloukas; Amna Malik; Jonathan M Carlson; Pieter Jooste; Anthony Ogwu; Roger Shapiro; Lynn Riddell; Fabian Chen; Graz Luzzi; Manjeetha Jaggernath; Gerald Jesuthasan; Katie Jeffery; Thumbi Ndung'u; Philip J R Goulder; Anna Maria Geretti; Paul Klenerman Journal: PLoS One Date: 2015-07-28 Impact factor: 3.240
Authors: Gilles Wandeler; Kalo Musukuma; Samuel Zürcher; Michael J Vinikoor; Jara Llenas-García; Mussa M Aly; Lloyd Mulenga; Benjamin H Chi; Jochen Ehmer; Michael A Hobbins; Carolyn Bolton-Moore; Christopher J Hoffmann; Matthias Egger Journal: PLoS One Date: 2016-03-31 Impact factor: 3.240
Authors: Philippa C Matthews; Jonathan M Carlson; Apostolos Beloukas; Amna Malik; Pieter Jooste; Anthony Ogwu; Roger Shapiro; Lynn Riddell; Fabian Chen; Graz Luzzi; Gerald Jesuthasan; Katie Jeffery; Nebojsa Jojic; Thumbi Ndung'u; Mary Carrington; Philip J R Goulder; Anna Maria Geretti; Paul Klenerman Journal: J Infect Dis Date: 2015-12-09 Impact factor: 5.226
Authors: Alexander J Stockdale; Mas Chaponda; Apostolos Beloukas; Richard Odame Phillips; Philippa C Matthews; Athanasios Papadimitropoulos; Simon King; Laura Bonnett; Anna Maria Geretti Journal: Lancet Glob Health Date: 2017-10 Impact factor: 26.763